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Gadoxetic Acid (Gd-EOB-DTPA)-Enhanced
MRI versus Gadobenate Dimeglumine
(Gd-BOPTA)-Enhanced MRI for
Preoperatively Detecting Hepatocellular
Carcinoma: an Initial Experience
Objective: This study was designed to compare the diagnostic performance of
gadoxetic acid-enhanced magnetic resonance imaging (MRI) with gadobenate
dimeglumine-enhanced MRI for preoperatively detecting hepatocellular carcino-
ma (HCC).
Materials and Methods: Eighteen consecutive patients (17 men and one
woman, age range: 31-73 years) with 22 HCCs underwent examinations with
gadoxetic acid enhanced MRI and gadobenate dimeglumine-enhanced MRI on a
3.0-Tesla unit. The diagnosis of HCC was established after surgical resection and
pathological conformation. Three observers independently reviewed each MR
image in a random order on a tumor-by-tumor basis. The diagnostic accuracy of
these techniques for the detection of HCC was assessed by performing an alter-
native free-response receiver operating characteristic (ROC) analysis. The sensi-
tivity and positive predictive values were evaluated.
Results: The average value of the area under the ROC curve (Az) for gadoxet-
ic acid enhanced MRI (0.887) was not significantly different from the Az (0.899)
for gadobenate dimeglumine-enhanced MRI (p > 0.05). The overall sensitivities
of gadoxetic acid enhanced MRI and gadobenate dimeglumine-enhanced MRI
were 80% and 83%, respectively, with no significant difference (p > 0.05). The dif-
ferences of the positive predictive values for the two contrast agents for each
observer were not statistically significant (p > 0.05).
Conclusion: The diagnostic performance of gadoxetic acid-enhanced MRI and
gadobenate dimeglumine-enhanced MRI for preoperatively detecting HCC is
quite similar.
arious liver contrast agents for magnetic resonance imaging (MRI) have
been developed to characterize focal hepatic lesions. Among these
agents, gadolinium-based hepatobiliary agents are advantageous to
utilize for the detection as well as the characterization of hepatic focal lesions. Two
gadolinium-based hepatobiliary agents have been clinically approved and are now
being used: gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (gadoxetic
acid disodium or Gd-EOB-DTPA; Primovist, Schering, Berlin, Germany) and gadobe-
nate dimeglumine (Gd-BOPTA/Dimeg, Multihance, Bracco, Milano, Italy). Both agents
are distributed in the extracellular-interstitial space immediately after intravenous
administration. Subsequently, the agents are taken up by functional hepatocytes,
which is a process mediated by organic anion transporter, and the compounds are
excreted into the bile (1-6). The biliary excretion rate of gadobenate dimeglumine is
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Vapproximately 3-5%, whereas the biliary excretion rate of
gadoxetic acid is up to 50% (1, 3-5, 7, 8). In addition,
gadoxetic acid has an advantage in terms of obtaining its
hepatobiliary phase as early as 20 min following contrast
injection, while gadobenate dimeglumine-enhanced MRI is
performed > 60 min following injection (9, 10).
For the detection of hepatocellular carcinoma (HCC) in
patients with chronic liver disease, gadobenate dimeglu-
mine-enhanced MRI has demonstrated a higher sensitivity
than has multidetector CT (MDCT) for HCCs (≤ 1 cm)
(11) and gadobenate dimeglumine-enhanced MRI has
demonstrated a better diagnostic performance than
ferucarbotran-enhanced MRI (12). However, to the best of
our knowledge, there have been no studies that have
compared gadoxetic acid-enhanced MRI and gadobenate
dimeglumine-enhanced MRI with a 3.0 Tesla unit for the
detection of HCC. The purpose of this study was to
evaluate and compare the diagnostic performance of these
two MRI methods for preoperatively detecting HCC.
MATERIALS AND METHODS
Study Population
This is a retrospective study. Between January 2007 and
January 2008, 65 consecutive patients who were suspected
of having HCCs based on a sonographic evaluation and the
presence of an elevated level of α -fetoprotein underwent
gadobenate dimeglumine-enhanced MRI at our institution.
Among these patients, 30 patients also underwent
gadoxetic acid-enhanced MRI. For all the patients,
gadoxetic acid-enhanced MRI was performed at an interval
of five to 29 days after performing gadobenate dimeglu-
mine-enhanced MRI. Of the 30 patients who also
underwent gadoxetic acid-enhanced MRI, 18 patients (17
men and one woman, age range: 31-73 years, mean age:
53.3 years) underwent hepatic surgery with identifying 22
pathologically proven HCCs and these 18 patients were
eventually enrolled in this study. Of these 18 patents, a
portion of these patients, who were enrolled in a previous
report (13), were included because this study’s retrospec-
tive study design. All the hepatic surgeries were performed
within five days from the last pre-operative gadoxetic acid
enhanced MRI. Seven patients underwent segmentectomy,
six patients underwent bisegmentectomy and five patients
underwent right lobectomy. The 22 HCCs ranged from 0.5
cm to 10.0 cm in diameter (two HCCs were < 1 cm in
diameter, six HCCs were 1 cm ≤ diameter < 2 cm, and 14
HCCS were ≥ 2 cm in diameter, mean diameter, 2.9 cm).
The histological grades of the tumors included two well-
differentiated HCCs, 17 moderately differentiated HCCs
and three poorly-differentiated HCCs. Twelve patients (11
patients with hepatitis B virus and one with hepatitis C
virus) had cirrhosis, five patients had chronic B virus
related hepatitis and one patient had a normal liver.
Written informed consent for the liver MRI examinations
were obtained from all the patients. Approval by the
Institutional Review Board was waived because this was a
retrospective study.
MR Imaging
MRI examinations were performed with a 3.0 Tesla
whole-body MR system (Intera Achieva 3.0T; Philips
Medical Systems, Best, The Netherlands) with a 6-channel
phased-array coil as the receiver coil. The MRI protocols
and sequences were as follows: a respiratory triggered T1-
weighted turbo-field-echo in-phase sequence (TR/TE: 10
ms/2.3 ms, flip angle: 15� , matrix: 288 × 230, bandwidth:
434.3 Hz per pixel), an out-of-phase sequence (TR/TE: 10
ms/3.45 ms, flip angle: 15� , matrix: 288 × 230,
bandwidth: 434.3 Hz per pixel), a respiratory-triggered
single-shot T2-weighted sequence with a reduction factor
of two or four (TR/TE: 1,342 ms/80 ms, flip angle: 90� ,
matrix: 320 × 256, bandwidth: 506.4 Hz per pixel), a
breath-hold multi-shot T2-weighted sequence with a
reduction factor of two or four (TR/TE: 2,161 ms/70 ms,
flip angle: 90� , matrix: 400 × 280, bandwidth: 235.2 Hz
per pixel), a respiratory-triggered single-shot heavily T2-
weighted sequence with a reduction factor of two or four
(TR/TE: 1,573 ms/160 ms, flip angle: 90� , matrix: 320 ×
256, bandwidth: 317.9 Hz per pixel) with a 5-7 mm
section thickness, a 1-mm to 2-mm intersection gap and a
field of view of 32-38 cm. A dose of 0.1 mL/kg (0.025
mmol/kg gadoxetic acid; 0.05 mmol/kg gadobenate
dimeglumine) contrast agent was manually administered
intravenously at a rate of 2 mL/sec, followed by a 20 mL
saline solution flush. For the contrast-enhanced MRI, the
unenhanced, arterial phase (20-35 sec), portal phase (70
sec), equilibrium phase (3 min) and hepatobiliary phase
sequences were obtained using T1-weighted three-
dimensional turbo-field-echo imaging (T1 high resolution
isotropic volume examination; THRIVE, Philips Medical
Systems, Best, The Netherlands) (TR/TE: 3.4 ms/1.8 ms,
flip angle: 10� , matrix: 336 × 206, bandwidth: 995.7 Hz
per pixel) with a 2 mm section thickness with no intersec-
tion gap and a field of view of 32-38 cm. The hepatobil-
iary phase images were obtained 20 minutes after the
administration of gadoxetic acid. For gadobenate dimeglu-
mine, the hepatobiliary phase images were obtained three
hours after the administration to minimize its extracellular
effect.
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Three radiologists who each had at least two years
experience with interpreting MR images reviewed all of
the MR images on a 2,000 × 2,000 picture archiving and
communications system (PACS; PathSpeed workstation;
GE Healthcare, Milwaukee, WI) workstation in a random
order and in a blinded fashion. They were unaware which
contrast agent was used when reading the images. The
interval between the reviews of the two MRI examinations
was at least one month. Each observer recorded the
presence and segment location of the HCC lesions by using
a four-point scale to assign a confidence level to each
lesion. The scores were 1: probably not an HCC lesion, 2:
a possible HCC lesion, 3: a probable HCC lesion and 4: a
definite HCC lesion. An HCC was defined as showing
typical arterial enhancement and venous washout irrespec-
tive of its size, based on previous studies (14-19). Nodules
larger than 2 cm with predominant hypointensity, as seen
on the contrast-enhanced portal and equilibrium phases
with no definite arterial enhancement, were also regarded
as HCCs (19, 20). In addition to these features, a
hypointense nodule seen on the hepatobiliary phase MR
images was considered as an HCC based on the findings of
a previous report (21). A hypervascular nodule seen on the
contrast-enhanced arterial phase with a washout pattern
was considered as an HCC, although the nodule was seen
with isointensity or hyperintensity relative to the surround-
ing liver parenchyma on the hepatobiliary phase (21, 22).
To achieve accurate correlation between the findings of the
scored lesions and the reference standard, each observer
recorded the individual image number, the locations of all
of the lesions and the diameter of each lesion. For patients
with multiple lesions located in the same segment, the
observers added further descriptions regarding the size and
location of the lesion within each segment in order to
avoid confusion during the data analysis. The sensitivities
were calculated using the number of lesions assigned a
confidence level of 3 or 4. All false-positive findings with
confidence levels of 3 or 4 and that were confirmed as
benign lesions, or all false-negative findings with
confidence levels of 1 or 2 and that were confirmed as an
HCC, were assessed by two study coordinators who
worked in consensus.
For the quantitative analysis, a radiologist chose the
regions of interest on the MR images. For heterogeneous
lesions, the regions of interest were chosen in the more
homogeneous areas. Areas of intratumoral necrosis or
hemorrhage were excluded from the regions of interest.
Measurements of tumors and the background along the
phase-encoding axis were obtained from the same areas on
the six images. The contrast-to-noise ratios (CNRs) were
calculated using (SIL-SIBL)/SDN, where SIL is the signal
intensity (SI) of the lesion, SDN is the standard deviation
of the background noise and SIBL is the mean SI of the
background liver. For measurement purposes, 17 tumors
that were 1 cm or more in diameter and visible on the
images obtained with all the pulse sequences were chosen
for the analysis in order to reduce any measurement
inaccuracies resulting from partial volume effects.
Statistical Analysis
On the basis of the three observers’ reviews, an alterna-
tive free-response receiver operating characteristic (ROC)
curve was generated on a tumor-by-tumor basis. The
diagnostic performance of each contrast agent for each
observer was assessed by measuring the area under the
ROC curve (Az), in accordance with a previous report
(23), and the average Az values for the two contrast agents
were compared as previously described by McNeil et al.
(24).
The sensitivity for each observer and technique was
calculated and the differences of the sensitivities were
assessed by the McNemar test. Statistical analysis for the
overall sensitivities of the two techniques for all observers
was assessed by the generalized estimating equation.
Statistical analyses for the differences of the calculated
positive predictive values for each observer and technique
were based on a previous study (25). A p value less than
0.05 was considered to indicate a statistically significant
difference. An analysis of all false-positive and false-
negative observations was also undertaken. Kappa statis-
tics were used to assess the interobserver agreement for
the detection of HCCs with the use of each technique. The
degree of agreement was categorized as follows: kappa
values of 0.00-0.20 were considered to indicate poor
agreement, kappa values of 0.21-0.40 indicated fair
agreement, kappa values of 0.41-0.60 indicated moderate
agreement, kappa values of 0.61-0.80 indicated good
agreement and kappa values of 0.81-1.00 indicated
excellent agreement (26).
In the quantitative image analysis, the tumor to liver
CNR of each phase was statistically compared using the
Wilcoxon signed ranks test. 
RESULTS
For all 22 HCCs evaluated, the calculated Az values for
each observer for the gadoxetic acid- and gadobenate
dimeglumine-enhanced MRI are shown in Table 1. All the
observers achieved similar diagnostic accuracy with the
two techniques (Fig. 1); the average Az values obtained for
the use of gadoxetic acid (0.887) and gadobenate dimeglu-
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Fig. 1. 50-year-old man with 1.8 cm moderately differentiated hepatocellular carcinoma (arrows) in liver segment VI.
A-C. Gadoxetic acid-enhanced transverse MR images show arterial enhancement (A), washout during equilibrium phase (B) and
hypointensity during hepatobiliary phase (C). This lesion was detected by all of observers. Tumor-to-liver contrast-to-noise ratios were
15, -2.1 and -30.1 during arterial, equilibrium and hepatobiliary phases, respectively.
D-F. Gadobenate dimeglumine-enhanced transverse MR images show arterial enhancement (D), no washout during equilibrium phase
(E) and hypointensity during hepatobiliary phase (F). This lesion was detected by all of observers. Tumor-to-liver contrast-to-noise ratios
were 36.7, 9.8 and -4.9, during arterial, equilibrium and hepatobiliary phases, respectively.
DEF
Table 1.Area Under Receiver Operating Curve (Az) for Gadoxetic Acid-Enhanced MRI and Gadobenate Dimeglumine-
Enhanced MRI for Detecting 22 Hepatocellular Carcinomas
Technique Observer 1 Observer 2 Observer 3 Average
Gadoxetic acid-enhanced MRI 0.903  0.864  0.894  0.887 
Gadobenate dimeglumine-enhanced MRI 0.942  0.870  0.886  0.899 
Difference in Az 0.039  0.007  0.008  0.012
P 0.293 0.782 0.865 0.780
Note.─ Data are given as Az values.mine enhanced MRI (0.899) for all the observers were not
significantly different (p = 0.780).
The sensitivities for each observer and each MRI
examination were calculated (Table 2). The difference in
the overall sensitivities of the two techniques for all the
observers was not statistically significant (p = 0.317). None
of the observers showed statistically significant differences
for the positive predictive values between the two
techniques (p > 0.05) (Table 2).
Gadoxetic acid-enhanced MRI resulted in identifying five
false positive lesions, and gadobenate dimeglumine-
enhanced MRI resulted in identifying seven false positive
lesions. Four lesions (80%) depicted on the gadoxetic acid-
enhanced MRI and five lesions (71%) depicted on the
gadobenate dimeglumine-enhanced MRI were identified as
arterioportal shunts. All nine lesions that were misinter-
preted by the three observers were the same three arterio-
portal shunts. One necrotic cirrhosis-related nodule was
misinterpreted as an HCC with both techniques. Another
necrotic cirrhosis-related nodule was misinterpreted as an
HCC only on the gadobenate dimeglumine-enhanced MRI. 
Gadoxetic acid-enhanced MRI depicted 13 false negative
lesions and gadobenate dimeglumine-enhanced MRI
depicted 11 false negative lesions. Three HCCs were not
detected using the two techniques by all the observers. The
sizes and histological grades of these three tumors were a
0.5 cm poorly-differentiated tumor, a 0.6 cm moderately-
differentiated tumor and a 1.3 cm well-differentiated
tumor. Based on a retrospective analysis, the 0.5 cm HCC
could not be seen on any images and the 0.6 cm HCC was
missed due to an error by the observers on a retrospective
review (Fig. 2). The well differentiated 1.3 cm HCC was
seen with isointensity relative to the surrounding liver on
the hepatobiliary phase images, with no hypervascularity
on the arterial phase and with hypointensity only on the
equilibrium phase of both MRI methods, which resulted in
the false-negative result in the retrospective analysis.
One moderately-differentiated HCC that was 1.1 cm in
the right liver dome was detected only on the gadobenate
dimeglumine-enhanced MR images by the two observers,
and it was not depicted on the gadoxetic acid-enhanced
MR images by any of the observers.
There was no HCC was detected only on the gadoxetic
acid-enhanced MR images and not on the gadobenate
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Table 3.Interobserver Agreement Regarding Presence of Hepatocellular Carcinoma
Technique Observer 1 versus Observer 2 Observer 2 versus Observer 3 Observer 1 versus Observer 3
Gadoxetic acid-enhanced MRI 0.856 0.761 0.904
Gadobenate dimeglumine-enhanced MRI 0.951 0.668 0.768
Note.─ Data are shown as kappa values.
Table 4.Contrast-to-Noise Ratio Patterns of 17 Hepatocellular Carcinomas over 1 cm
Technique AP PP EP  HBP
Gadoxetic acid-enhanced MRI -8.7~21 (4.0) -9.9~13.4 (-1.8) -16.2~5.6 (-6.8) -34.4~-3.4 (-16.1)
Gadobenate dimeglumine-enhanced MRI -13.8~36.7 (7.3) -11.1~14.7 (-0.4) -12.7~16.1 (0.7) -25.5~-0.8 (-8.3)
P 0.309 0.492 0.478 0.000
Note.─ Data shown are range of contrast-to-noise ratios and data in parentheses are mean of contrast-to-noise ratio.
AP = arterial phase, EP = equilibrium phase, HBP = hepatobiliary phase, PP = portal phase
Table 2.Sensitivities and Positive Predictive Values of Gadoxetic Acid-Enhanced MRI and Gadobenate Dimeglumine-
Enhanced MRI for Detecting 22 Hepatocellular Carcinomas
Technique Observer 1 Observer 2 Observer 3 Overall
Sensitivity per Lesion (%)
a
Gadoxetic acid-enhanced MRI 81.8 (18) 77.3 (17) 81.8 (18) 80.3 (53)
Gadobenate dimeglumine-enhanced MRI 86.4 (19) 81.8 (18) 81.8 (18) 83.3 (55)
Positive Predictive Value (%)
b
Gadoxetic acid-enhanced MRI 94.7 (18/19) 85.0 (17/20) 94.7 (18/19)
Gadobenate dimeglumine-enhanced MRI 90.5 (19/21) 94.7 (18/19) 81.8 (18/22)
Note.─
aData in parentheses are number of true-positive lesions. 
bData in parentheses are number of true-positive lesions divided by total number of 
lesions assigned confidence level of 3 or 4. Differences of sensitivities and positive predictive values for two techniques for each observer are not
statistically significant (p > 0.05).dimeglumine-enhanced MR images. The kappa values
among the three observers showed good and excellent
agreement for the two techniques (Table 3).
Table 4 showed the range of the CNRs of 17 HCCs
during the four phases, respectively. All the tumors had
the maximum absolute CNR during the arterial or hepato-
biliary phase. The differences of the CNR during each of
the four phases were statistically significant only during the
hepatobiliary phase (Fig. 1). 
DISCUSSION
High-field-strength MRI and the development of
techniques such as parallel imaging has resulted in an
increase of the signal-to-noise ratio, reduction of motion
artifacts and better conditions that minimize the scan time
and improve MR imaging (27-30). In addition to the MRI
techniques, the development of hepatic contrast agents is a
major factor for achieving better diagnostic accuracy of
hepatic focal lesions. Gadoxetic acid, which has recently
been used in clinical practice, is the second gadolinium-
based hepatobiliary agent developed for clinical use and it
is advantageous as the hepatobiliary phase can be obtained
at 10 or 20 minutes post-injection, as compared with that
of gadobenate dimeglumine for which the hepatobiliary
phase can be obtained at 1-3 hours post-injection.
Gadoxetic acid also has a potential merit, due to its high
rate of biliary excretion, for use in patients who are at risk
Park et al.
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Fig. 2. 47-year-old man with 0.6 cm
moderate-differentiated hepatocellular
carcinoma (arrows) in liver segment VI.
A, B. Gadoxetic acid-enhanced
transverse MR images show arterial
enhancement (A), washout during
equilibrium phase (not shown) and
hypointensity during hepatobiliary phase
(B). All of observers missed this lesion.
C, D. Gadobenate dimeglumine-
enhanced transverse MR images show
arterial enhancement (C), washout
during equilibrium phase (not shown)
and hypointensity during hepatobiliary
phase (D). All of observers missed this
lesion.of nephrogenic systemic sclerosis. Since the biliary
excretion rate of gadoxetic acid is superior to that of
gadobenate dimeglumine, we thought that the strong
enhancement of the liver parenchyma and the high CNR
during the hepatobiliary phase of gadoxetic acid-enhanced
MRI might result in improved diagnostic accuracy for
detecting HCCs and this would be similar as that of
gadobenate dimeglumine-enhanced MRI.
On our quantitative analysis, there was a significant
difference of CNRs during hepatobiliary phase, and this
difference is based on the higher bile excretion rate of
gadoxetic acid than that of gadobenate dimeglumine. Yet
the two imaging techniques had similar diagnostic
accuracy, sensitivity and positive predictive values. One
possible reason for this is that the precontrast scans and
dynamic imaging to assess the hemodynamics of the lesions
were similar for both contrast agents. Second, although the
estimated relaxivity of gadoxetic acid is 16.6 mmol-1s-1
and this is lower than that of gadobenate dimeglumine (6),
the earlier and rapider biliary excretion of gadoxetic acid
may compensate for this disadvantage and improve the
CNR during the hepatobiliary phase, which helped to
obtain comparable results using both contrast agents. 
In our study, the majority of false positive lesions on
both the gadoxetic acid-enhanced MRI (80%) and the
gadobenate dimeglumine-enhanced MRI (71%) were
primarily attributed to an arterioportal shunt. We believe
that an arterioportal shunt is an important mimicker of
HCC that causes difficulty to differentiate small HCCs on
both the gadoxetic acid- and gadobenate dimeglumine-
enhanced dynamic MR images. On the retrospective
review, all of the arterioportal shunts showed no
hypointensity on the hepatobiliary phase images, which
may be helpful for differentiating these lesions from small
HCCs. In a recent study, most of the arterial-enhancing
pseudo lesions showed isointensity during the hepatobil-
iary phase and a few lesions showed hypointensity on the
gadoxetic acid-enhanced MRI (31).
There were three false negative lesions for both contrast
agents by all the observers. Two of them were too small to
detect. One was due to the detection error and the other
was due to no delineation even though the images of both
MRI examinations were retrospectively reviewed. The
remaining false negative lesion, a 1.3 cm HCC, was seen
with isointensity on the unenhanced, arterial and hepato-
biliary images, but this lesion was seen with hypointensity
only on the equilibrium phase for both MRI contrast
agents. All of the observers misinterpreted the lesion as a
benign cirrhosis-related nodule because of the atypical
enhancement. We think that one possible reason observers
misinterpret or miss HCCs in clinical practice may be due
to the hyper- or isointensity of HCCs during the hepatobil-
iary phase of MRI with using both contrast agents.
Therefore, one should be aware that HCC cannot be
completely ruled out when HCC tumors in patients with
chronic liver disease show iso- or hyperintensity on the
hepatobiliary phase images, as several investigators have
reported the paradoxical uptake of gadoxetic acid or
gadobenate dimeglumine in HCC (21, 32). Another
possible reason is that small HCC and well differentiated
HCC can have the atypical enhancement, such as the lack
of arterial hypervascularity (33). 
One 1.1 cm HCC was interpreted correctly only on the
gadobenate dimeglumine enhanced MRI by two observers.
As seen on the gadobenate dimeglumine-enhanced MR
images, the presence of arterial nodular enhancement
allowed making an exact diagnosis in spite of the presence
of isointensity seen on the unenhanced and equilibrium
phase images and the hyperintensity seen on the hepatobil-
iary images, while arterial hypervascularity was not found
on the gadoxetic acid-enhanced MR images. We can
speculate that in addition to the technical errors due to the
location of the tumor in the liver dome, a lesser concentra-
tion of gadoxetic acid, as compared to that of gadobenate
dimeglumine, may lead to the loss of arterial hypervascu-
larity on the gadoxetic acid-enhanced MR images.
This study has some limitations. First, the enrolled
population was not sufficient to completely verify the
diagnostic performance, and the small population may
have led to the detection of a small number of false
positive lesions. Second, the study group was limited to
patients with good hepatic function and so they could
undergo hepatic resection, and this limitation might have
caused a selection bias that may have resulted in a higher
diagnostic performance.
In conclusion, gadoxetic acid-enhanced MRI and gadobe-
nate dimeglumine-enhanced MRI have similar diagnostic
performances for preoperatively detecting HCCs in
patients with chronic liver disease.
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